Aligos Therapeutics, Inc. (ALGS) vs Pluri Inc. (PLUR)

Aligos Therapeutics, Inc. and Pluri Inc. are both Biotechnology companies. Aligos Therapeutics, Inc. and Pluri Inc. are of similar size ($14.0M and $13.7M). Aligos Therapeutics, Inc. grew revenue faster over the last twelve months: 1,171.6% against 10.0%. Aligos Therapeutics, Inc. has the higher net margin (−197.0% vs −1,943.9%) and the higher return on invested capital (0.00% vs −690.2%). Across the 16 metrics below, Aligos Therapeutics, Inc. leads on 11 and Pluri Inc. on 5.

Valuation

Metric ALGS PLUR Biotechnology median
P/E n/m n/m 11.36
P/S 0.66 9.01 9.12
P/B 1.95 n/m 2.14
Price to free cash flow n/m n/m 26.34
EV/EBITDA 0.13 n/m 0.62
EV/Sales (0.28) 23.14 8.56
Earnings yield (300.95%) (245.37%) (34.18%)
Free cash flow yield (311.04%) (146.92%) (23.62%)

Profitability

Metric ALGS PLUR Biotechnology median
Gross margin 100.00% 51.95% 67.24%
Operating margin (215.55%) (2,341.12%) 0.00%
Net margin (197.01%) (1,943.87%) 0.00%
Free cash flow margin (204.07%) (1,282.11%) 0.00%
Return on equity (159.46%) 253.49% (50.28%)
Return on assets (84.46%) (96.79%) (45.89%)
Return on invested capital 0.00% (690.21%) 0.00%

Growth

Metric ALGS PLUR Biotechnology median
Revenue growth (TTM) 1,171.58% 10.03% 6.96%
EPS growth (last fiscal year) 88.30% 31.46% 29.86%
Revenue growth, 5-year CAGR — 113.32% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALGS PLUR Biotechnology median
Debt to equity 0.00 (1.65) 0.00
Current ratio 1.77 0.27 4.72
Net debt to EBITDA 0.87 (0.83) 1.01

Dividend

Metric ALGS PLUR Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric ALGS PLUR Biotechnology median
Market cap 13.95m 13.74m 167.45m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack